export const case67 = {
    id: "case-67",
    slug: "reanalysis-with-changed-classification-case",
    title: "Case 67: Reanalysis with changed classification",
    level: "Advanced",
    summary:
      "A guided case focused on reanalysis where updated gene evidence, variant evidence, segregation data, and population information change how previous findings should be prioritised.",
  
    visualisationExampleId: null,
  
    assessmentFocus: [
      "Reanalysis reasoning",
      "Changed classification",
      "Updated gene-disease evidence",
      "Updated population evidence",
      "Variant reprioritisation",
      "Safe communication of changed interpretation",
    ],
  
    guidedTutorMode: {
      type: "static-rule-based",
      description:
        "Uses built-in hints, checkpoint feedback, model answers, and self-check criteria to support safe case reasoning.",
    },
  
    phase5Assessment: {
      candidateRanking: {
        prompt:
          "Rank the findings from strongest to weakest based on the updated reanalysis evidence, not only the original analysis notes.",
        correctOrder: [
          "candidate-3",
          "candidate-5",
          "candidate-2",
          "candidate-4",
          "candidate-1",
        ],
        explanation:
          "Candidate 3 is strongest because updated gene-disease validity, additional affected individuals, improved variant evidence, continued phenotype fit, de novo inheritance, and technical confidence now support formal review more strongly than in the original analysis. Candidate 5 is central because it explains the reanalysis context and why evidence has changed. Candidate 2 was previously plausible but is now weaker after updated population and mechanism review. Candidate 4 is likely a real CNV but remains weak because dosage and inheritance support are limited. Candidate 1 is broad, inherited, relatively frequent, and poorly specific.",
      },
  
      escalationDecision: {
        prompt:
          "Choose the safest next action for the finding whose interpretation has strengthened during reanalysis.",
        options: [
          {
            id: "report-old-vus-language",
            label: "A",
            decision:
              "Keep Candidate 3 at the old VUS-level wording because the original report should not be changed during reanalysis.",
            isBest: false,
            feedback:
              "Review this choice. Reanalysis is specifically designed to reconsider findings when evidence changes.",
          },
          {
            id: "diagnose-without-review",
            label: "B",
            decision:
              "Report Candidate 3 as diagnostic immediately because new evidence has made it more convincing.",
            isBest: false,
            feedback:
              "Review this choice. The finding is stronger, but changed interpretation still requires formal review, documentation, and sign-off.",
          },
          {
            id: "escalate-reanalysis-review",
            label: "C",
            decision:
              "Escalate Candidate 3 for formal reanalysis review, documenting which evidence has changed and how confidence has increased.",
            isBest: true,
            feedback:
              "Best decision. The updated evidence makes Candidate 3 review-worthy, but the changed interpretation should be formally reviewed and documented.",
          },
        ],
      },
  
      writtenSummary: {
        prompt:
          "Write a short trainee-level handover summary explaining why the reanalysis changes the prioritisation, which finding has strengthened, and which previous finding has weakened.",
        checklist: [
          "Names Candidate 3 as the strongest current finding.",
          "Explains what evidence has changed since the original analysis.",
          "Mentions updated gene-disease validity, additional cases, variant evidence, phenotype fit, inheritance, and technical support.",
          "Explains that Candidate 2 has weakened after updated population or mechanism review.",
          "Avoids saying the old interpretation was wrong without explaining the evidence change.",
          "Recommends formal reanalysis review and clinical laboratory sign-off.",
        ],
        modelAnswer:
          "Candidate 3 is now the strongest current finding for formal reanalysis review. In the original analysis it was treated cautiously because the gene-disease evidence and variant-level evidence were limited. Since then, updated evidence has strengthened the case: additional affected individuals with overlapping neurodevelopmental and epilepsy phenotypes have been reported in the local teaching summary, the gene-disease association is now stronger, nearby or same-domain variants have more supportive evidence, and the variant remains rare, technically convincing, apparently de novo, and a good phenotype fit. Candidate 5 is the central reanalysis context because it explains why the conclusion can change when evidence changes. Candidate 2 has moved in the opposite direction: updated population and mechanism review make it less convincing than before. Candidate 4 is likely a real CNV but remains weak due to uncertain dosage and inheritance support, and Candidate 1 is broad, inherited, relatively frequent, and poorly specific. The safest next step is to escalate Candidate 3 for formal reanalysis review and sign-off, clearly documenting what changed since the original interpretation.",
      },
    },
  
    reasoningScorecard: [
      {
        category: "Reanalysis awareness",
        maxScore: 2,
        expectation:
          "Recognises that reanalysis can change candidate priority when gene evidence, variant evidence, population data, or phenotype information changes.",
      },
      {
        category: "Changed evidence reasoning",
        maxScore: 2,
        expectation:
          "Identifies which evidence has strengthened or weakened rather than simply repeating the old interpretation.",
      },
      {
        category: "Candidate prioritisation",
        maxScore: 2,
        expectation:
          "Prioritises the finding with the strongest current evidence, even if it was previously uncertain.",
      },
      {
        category: "Evidence interpretation",
        maxScore: 2,
        expectation:
          "Balances updated gene validity, variant evidence, inheritance, phenotype fit, population data, and technical confidence.",
      },
      {
        category: "Safe communication",
        maxScore: 2,
        expectation:
          "Communicates changed interpretation carefully, with traceable evidence and formal review boundaries.",
      },
    ],
  
    patient: {
      age: 12,
      sex: "Female",
    },
  
    referralReason:
      "A 12-year-old girl has been referred for reanalysis of previous rare disease genome sequencing because of global developmental delay, severe speech delay, epilepsy, hypotonia, autistic features, feeding difficulties in early childhood, and mild dysmorphic features. The original analysis did not identify a diagnostic finding. Two findings were previously kept at uncertain or low-priority level. New gene-disease evidence, updated variant information, and updated population review may change the prioritisation.",
  
    testType:
      "Rare disease genome reanalysis with SNV/indel, CNV, updated gene-disease evidence, population update, phenotype review, and technical-confidence review",
  
    familyStructure:
      "The proband and both biological parents were tested in the original trio genome analysis. Both parents are reportedly unaffected. No known consanguinity is reported. The reanalysis uses the existing trio data plus updated interpretation evidence.",
  
    history: [
      "Global developmental delay noted in infancy",
      "Severe expressive speech delay",
      "Epilepsy beginning at age 4",
      "Generalised hypotonia",
      "Autistic features reported by the clinical team",
      "Feeding difficulties in early childhood",
      "Mild dysmorphic features noted by clinical genetics",
      "No previous confirmed molecular diagnosis",
      "Original genome analysis reported no diagnostic finding",
      "Reanalysis requested because new gene and variant evidence may now be available",
      "Both parents are reportedly unaffected",
    ],
  
    phenotype: [
      "Global developmental delay",
      "Severe speech delay",
      "Epilepsy",
      "Hypotonia",
      "Autistic features",
      "Feeding difficulties",
      "Mild dysmorphic features",
      "Reanalysis after previous uncertain findings",
    ],
  
    familyHistory:
      "Both parents are reportedly unaffected. There is no known family history of developmental delay, epilepsy, hypotonia, autistic features, severe speech delay, feeding difficulties, dysmorphic features, or a similar neurodevelopmental presentation.",
  
    serviceContext: [
      "This guided case focuses on reanalysis with changed interpretation.",
      "The key issue is that previous findings should not be interpreted only using the original evidence snapshot.",
      "The learner should not assume the original VUS-level or low-priority conclusion must stay unchanged forever.",
      "The learner should also not automatically upgrade a finding just because time has passed.",
      "The safest conclusion should explain exactly what evidence has changed and how that affects prioritisation.",
      "The final handover should be traceable, cautious, and clear about formal review and sign-off.",
    ],
  
    candidateFindings: [
      {
        id: "candidate-1",
        label: "Candidate 1",
        gene: "BROADREAN1",
        variant: "chr2:77190442 C>T",
        zygosity: "Heterozygous",
        consequence: "missense_variant",
        inheritanceSignal: "Inherited from unaffected mother",
        clinicalFit:
          "BROADREAN1 has a broad neurodevelopmental association in limited reports, but the variant is inherited from the unaffected mother, relatively frequent, and still does not explain the epilepsy-led presentation well.",
        rawEvidence: `GENE: BROADREAN1
  Known disease association in original analysis: broad neurodevelopmental association in limited reports
  Updated gene-disease evidence: still limited
  Reported inheritance: autosomal dominant proposed
  Known mechanism: uncertain
  
  Variant:
  chr2:77190442 C>T
  Transcript: NM_670001.2
  HGVS: c.899C>T p.(Pro300Leu)
  Consequence: missense_variant
  Protein domain: outside proposed recurrent functional region
  
  VCF-style fields:
  QUAL=684
  FILTER=PASS
  INFO: DP=46;MQ=60;QD=14.9;SOR=0.84
  FORMAT: GT:AD:DP:GQ
  
  Proband blood: 0/1:23,23:46:99
  Mother blood: 0/1:22,22:44:99
  Father blood: 0/0:42,0:42:99
  
  Read-level notes:
  ALT reads seen on both forward and reverse strands
  ALT reads distributed across read positions
  No local mapping warning
  No concerning soft-clipping
  Second caller: detected
  
  Original population review:
  gnomAD AF = 0.0009
  
  Updated population review:
  gnomAD AF = 0.0013
  gnomAD allele count = 365
  One homozygote observed in local population summary
  
  Phenotype fit:
  Developmental delay: broad possible overlap
  Severe speech delay: broad possible overlap
  Epilepsy: limited overlap
  Hypotonia: weak overlap
  Autistic features: broad possible overlap
  Feeding difficulties: not a core feature
  
  Review question:
  Assess whether this inherited, relatively frequent, broad-match finding has become stronger on reanalysis.`,
        concern:
          "This remains weak. Reanalysis has not provided enough new evidence to make it a strong candidate.",
      },
      {
        id: "candidate-2",
        label: "Candidate 2",
        gene: "OLDVUS2",
        variant: "chr8:44198221 G>A",
        zygosity: "Heterozygous",
        consequence: "missense_variant",
        inheritanceSignal: "Absent from both parents on standard genotype calls",
        clinicalFit:
          "OLDVUS2 was previously considered a plausible VUS-level candidate. Updated review shows weaker gene validity, less convincing mechanism support, and a slightly higher population frequency than originally appreciated.",
        rawEvidence: `GENE: OLDVUS2
  Original gene-disease evidence: possible autosomal dominant developmental epilepsy association
  Updated gene-disease evidence: limited / disputed in local reanalysis summary
  Reported inheritance: de novo reported in small numbers originally
  Known mechanism: uncertain; missense mechanism not clearly established
  
  Variant:
  chr8:44198221 G>A
  Transcript: NM_670002.4
  HGVS: c.1286G>A p.(Arg429His)
  Consequence: missense_variant
  Protein domain: originally thought to be a functional domain
  Updated domain review: domain relevance less clear
  
  VCF-style fields:
  QUAL=812
  FILTER=PASS
  INFO: DP=52;MQ=60;QD=15.6;SOR=0.78
  FORMAT: GT:AD:DP:GQ
  
  Proband blood: 0/1:26,26:52:99
  Mother blood: 0/0:44,0:44:99
  Father blood: 0/0:45,0:45:99
  
  Read-level notes:
  ALT reads seen on both forward and reverse strands
  ALT reads distributed across read positions
  High mapping quality
  No local low-complexity warning
  Second caller: detected
  
  Original interpretation:
  Rare de novo missense candidate
  Kept as VUS-level because phenotype overlap was possible
  
  Updated population review:
  gnomAD AF = 0.00008
  gnomAD allele count = 27
  No homozygotes observed in local summary
  Frequency is still rare but less compelling for a severe highly penetrant de novo disorder
  
  Updated ClinVar / literature-style review:
  No exact matching pathogenic record found
  Several nearby variants previously considered candidate-level have since been submitted as VUS or likely benign
  No clear functional evidence for this exact variant
  Gene-disease validity remains limited
  
  Phenotype fit:
  Developmental delay: compatible
  Epilepsy: compatible
  Severe speech delay: compatible
  Hypotonia: partial overlap
  Feeding difficulties: weak overlap
  Autistic features: variable
  
  Review question:
  Assess whether a previously plausible VUS-level candidate has strengthened or weakened after updated evidence.`,
        concern:
          "This has weakened compared with the original review. It is still technically real but should not be the leading candidate now.",
      },
      {
        id: "candidate-3",
        label: "Candidate 3",
        gene: "RECLASS3",
        variant: "chr12:66190442 G>A",
        zygosity: "Heterozygous",
        consequence: "missense_variant",
        inheritanceSignal: "Apparent de novo with good parental coverage",
        clinicalFit:
          "RECLASS3 was previously a VUS-level candidate because gene-disease evidence was limited. Updated reanalysis now supports a stronger association with a neurodevelopmental epilepsy syndrome, and the variant remains rare, technically strong, de novo, and phenotype-compatible.",
        rawEvidence: `GENE: RECLASS3
  Original gene-disease evidence: emerging neurodevelopmental epilepsy association
  Original interpretation: VUS-level candidate, not enough evidence for strong prioritisation
  Updated gene-disease evidence: moderate / established in local reanalysis summary
  Reported inheritance: usually de novo
  Known mechanism: damaging missense variants in a recurrent functional domain
  Updated mechanism review: missense clustering in the affected domain now better supported
  
  Variant:
  chr12:66190442 G>A
  Transcript: NM_670003.5
  HGVS: c.1370G>A p.(Gly457Glu)
  Consequence: missense_variant
  Protein domain: recurrent neurodevelopmental functional domain
  Updated domain review: multiple affected individuals now reported with damaging variants in this domain
  
  VCF-style fields:
  QUAL=948
  FILTER=PASS
  INFO: DP=56;MQ=60;QD=16.9;SOR=0.72
  FORMAT: GT:AD:DP:GQ
  
  Proband blood: 0/1:28,28:56:99
  Mother blood: 0/0:46,0:46:99
  Father blood: 0/0:45,0:45:99
  
  Read-level notes:
  ALT reads seen on both forward and reverse strands
  ALT reads distributed across read positions
  High base quality at variant position
  High mapping quality for ALT-supporting reads
  No local low-complexity warning
  No pseudogene or segmental duplication warning
  No concerning soft-clipping
  Second caller: detected
  
  Parental coverage:
  Mother has good coverage with no ALT support
  Father has good coverage with no ALT support
  Trio identity checks are consistent
  
  Population:
  Original review: not observed in available local population summary
  Updated review: gnomAD AF = not observed
  Updated review: gnomAD allele count = 0
  
  Updated ClinVar / literature-style review:
  No exact same variant confirmed as pathogenic in local summary
  New affected individuals reported with overlapping developmental delay, epilepsy, speech delay, hypotonia, and autistic features
  Several same-domain missense variants now have stronger submissions or published-style support
  Functional evidence for this exact variant is still not available
  
  Phenotype fit:
  Global developmental delay: strong match
  Severe speech delay: strong match
  Epilepsy: strong match
  Hypotonia: compatible
  Autistic features: compatible
  Feeding difficulties: compatible
  Mild dysmorphic features: variable
  
  Interpretation change:
  Original review: plausible VUS-level candidate
  Updated review: stronger candidate for formal reanalysis review
  Still requires formal classification and clinical laboratory sign-off
  
  Review question:
  Assess whether the updated evidence supports reprioritising this finding above the previous VUS-level candidates.`,
        concern:
          "This is now the strongest current candidate for formal reanalysis review, but the changed interpretation still needs formal review and sign-off.",
      },
      {
        id: "candidate-4",
        label: "Candidate 4",
        gene: "CNVREAN4 region",
        variant: "chr16:29120000-29205000 duplication",
        zygosity: "Heterozygous duplication",
        consequence: "copy_number_gain",
        inheritanceSignal: "Inherited from unaffected father",
        clinicalFit:
          "The duplication is likely real and was seen in the original analysis, but updated review still shows uncertain triplosensitivity, population overlap, and weak phenotype specificity.",
        rawEvidence: `CNV REGION: chr16:29120000-29205000
  CNV type: duplication
  Estimated size: 85 kb
  Copy-number state: heterozygous duplication
  
  Gene:
  CNVREAN4
  Known disease association in original analysis: possible developmental association in limited reports
  Updated gene-dosage evidence: triplosensitivity still not established
  Known mechanism: uncertain
  
  Inheritance:
  Proband: duplication present
  Mother: duplication not detected
  Father: duplication present
  
  CNV caller summary:
  Caller 1: duplication PASS
  Caller 2: duplication supported
  Quality score: 104
  Number of affected targets/windows: 25
  
  Read-depth evidence:
  Expected normalised depth in diploid regions: ~1.00
  Proband normalised depth across interval: ~1.47
  Father normalised depth across interval: ~1.48
  Mother normalised depth across interval: ~1.00
  Flanking regions: mostly normal
  
  Original interpretation:
  Likely real inherited CNV
  Clinical relevance uncertain
  
  Updated population / dosage review:
  Overlapping duplications observed in local population CNV summary
  Partial benign overlap reported
  No new convincing triplosensitivity evidence in local summary
  
  Phenotype fit:
  Developmental delay: broad possible overlap
  Epilepsy: weak overlap
  Hypotonia: weak overlap
  Feeding difficulties: not a core feature
  Autistic features: variable
  
  Review question:
  Assess whether this inherited duplication has become stronger during reanalysis.`,
        concern:
          "This is likely technically real but remains weak because the dosage mechanism and phenotype support have not strengthened.",
      },
      {
        id: "candidate-5",
        label: "Candidate 5",
        gene: "Reanalysis evidence review",
        variant: "Updated evidence changes candidate priority",
        zygosity: "Case-level reanalysis issue",
        consequence: "reanalysis_context",
        inheritanceSignal: "Affects interpretation of previous findings",
        clinicalFit:
          "This is not a disease candidate. It is the central interpretation issue: reanalysis can strengthen one previous candidate and weaken another when new evidence becomes available.",
        rawEvidence: `CASE CONTEXT REVIEW: reanalysis with changed evidence
  Original analysis outcome:
  No diagnostic finding reported
  Candidate 2 and Candidate 3 were both considered uncertain
  Candidate 4 was documented as a likely real but weak inherited CNV
  Candidate 1 was deprioritised
  
  What has changed:
  RECLASS3 gene-disease evidence has strengthened
  More affected individuals with overlapping neurodevelopmental epilepsy phenotypes are now described in the local reanalysis summary
  Same-domain missense evidence for RECLASS3 is stronger
  RECLASS3 variant remains absent from population data
  RECLASS3 remains apparently de novo with good parental coverage
  
  What has weakened:
  OLDVUS2 gene-disease evidence is less convincing than originally thought
  Updated population review shows the OLDVUS2 variant is rarer than common variation but not as compelling as first believed
  Nearby OLDVUS2 variant submissions remain uncertain or likely benign
  Mechanism support for OLDVUS2 remains unclear
  
  Important principle:
  Reanalysis is not just repeating the old report.
  Reanalysis asks whether current evidence changes confidence, priority, or communication.
  Changed interpretation must be traceable.
  Changed interpretation still requires formal review and sign-off.
  
  Review question:
  Assess how updated evidence should change candidate ranking and final handover.`,
        concern:
          "This is the central case context. The final handover should explain what changed rather than simply saying a variant was upgraded.",
      },
    ],
  
    decisionCheckpoints: [
      {
        id: "checkpoint-1",
        title: "Checkpoint 1 — Identify the reanalysis lead",
        context:
          "Candidate 3 was previously VUS-level, but updated evidence now strengthens the gene-disease and same-domain variant support.",
        question:
          "Which finding should be prioritised for formal reanalysis review?",
        options: [
          {
            label: "A",
            text: "Candidate 2, because it was already considered plausible in the original analysis and should remain the main candidate.",
            isCorrect: false,
            feedback:
              "Not quite. Candidate 2 has weakened after updated population and mechanism review.",
          },
          {
            label: "B",
            text: "Candidate 3, because the current evidence now gives the strongest convergence across gene, variant, inheritance, phenotype, and technical support.",
            isCorrect: true,
            feedback:
              "Correct. Reanalysis should use the current evidence, not just preserve the old ranking.",
          },
          {
            label: "C",
            text: "Candidate 4, because CNVs are more stable across reanalysis than changing missense evidence.",
            isCorrect: false,
            feedback:
              "Not quite. Candidate 4 is likely real, but dosage and phenotype support remain weak.",
          },
        ],
        teachingPoint:
          "Reanalysis can change which finding is most important when evidence changes.",
      },
      {
        id: "checkpoint-2",
        title: "Checkpoint 2 — Explain what changed",
        context:
          "Candidate 3 has not changed technically; the interpretation has changed because external evidence and gene validity have improved.",
        question:
          "What is the safest way to explain the change?",
        options: [
          {
            label: "A",
            text: "The original laboratory missed the variant, so the case should now be treated as an obvious diagnosis.",
            isCorrect: false,
            feedback:
              "Not quite. The variant was known before; what changed is the evidence available for interpretation.",
          },
          {
            label: "B",
            text: "The variant should stay unchanged forever because previous reports should not be revised.",
            isCorrect: false,
            feedback:
              "Not quite. Reanalysis exists because evidence and interpretation can change over time.",
          },
          {
            label: "C",
            text: "The same variant is now more review-worthy because updated gene-disease and variant evidence increase confidence.",
            isCorrect: true,
            feedback:
              "Correct. This explains the changed interpretation without implying the original review was careless.",
          },
        ],
        teachingPoint:
          "Changed classification should be explained as changed evidence, not simply as old versus new opinion.",
      },
      {
        id: "checkpoint-3",
        title: "Checkpoint 3 — Handle the weakened previous candidate",
        context:
          "Candidate 2 was previously plausible, but updated population and mechanism review make it less convincing.",
        question:
          "How should Candidate 2 be handled now?",
        options: [
          {
            label: "A",
            text: "Keep it as the main candidate because previous VUS-level findings should not be downgraded during reanalysis.",
            isCorrect: false,
            feedback:
              "Not quite. Reanalysis can lower priority when updated evidence weakens the case.",
          },
          {
            label: "B",
            text: "Document that it has weakened relative to Candidate 3 because current evidence is less supportive.",
            isCorrect: true,
            feedback:
              "Correct. Reanalysis should record both strengthened and weakened evidence.",
          },
          {
            label: "C",
            text: "Delete it completely from the reasoning because weakened candidates should never be mentioned.",
            isCorrect: false,
            feedback:
              "Not quite. It may still be useful to document why a previous candidate is no longer leading.",
          },
        ],
        teachingPoint:
          "Good reanalysis is traceable: it explains why previous candidates move up or down.",
      },
      {
        id: "checkpoint-4",
        title: "Checkpoint 4 — Avoid overcalling the reclassified finding",
        context:
          "Candidate 3 is stronger than before, but the exact variant is not confirmed as pathogenic in the local summary and no functional assay is available.",
        question:
          "Which wording is safest?",
        options: [
          {
            label: "A",
            text: "Candidate 3 is now a stronger review-worthy candidate, but formal classification and sign-off are still required.",
            isCorrect: true,
            feedback:
              "Correct. This balances strengthened evidence with safe reporting boundaries.",
          },
          {
            label: "B",
            text: "Candidate 3 is automatically diagnostic because any strengthened VUS should become pathogenic after reanalysis.",
            isCorrect: false,
            feedback:
              "Not quite. Strengthened evidence does not automatically equal diagnostic classification.",
          },
          {
            label: "C",
            text: "Candidate 3 should be ignored because reanalysis cannot use new literature or gene-disease evidence.",
            isCorrect: false,
            feedback:
              "Not quite. Updated evidence is central to reanalysis.",
          },
        ],
        teachingPoint:
          "A finding can become stronger without becoming automatically diagnostic.",
      },
      {
        id: "checkpoint-5",
        title: "Checkpoint 5 — Final reanalysis conclusion",
        context:
          "You need to prepare a safe trainee-level conclusion for formal clinical laboratory review.",
        question:
          "Which conclusion is safest?",
        options: [
          {
            label: "A",
            text: "Keep the original no-candidate conclusion unchanged because reanalysis should avoid changing previous reports.",
            isCorrect: false,
            feedback:
              "Not quite. Reanalysis should update conclusions when evidence has materially changed.",
          },
          {
            label: "B",
            text: "Prioritise Candidate 3 for formal reanalysis review and document which evidence has strengthened since the original analysis.",
            isCorrect: true,
            feedback:
              "Correct. This conclusion is updated, traceable, and safe.",
          },
          {
            label: "C",
            text: "Report Candidate 2 and Candidate 3 as equal because both have been uncertain at some point.",
            isCorrect: false,
            feedback:
              "Not quite. Current evidence supports Candidate 3 more strongly than Candidate 2.",
          },
        ],
        teachingPoint:
          "Safe reanalysis updates the candidate ranking while making the evidence change transparent.",
      },
    ],
  
    finalReflection:
      "A safe trainee-level conclusion would be that Candidate 3 is now the strongest current finding for formal reanalysis review. In the original analysis, RECLASS3 was kept at VUS-level because gene-disease validity and same-domain evidence were limited. Updated reanalysis now provides stronger support: the gene-disease association is better established in the local reanalysis summary, additional affected individuals have overlapping developmental delay, epilepsy, severe speech delay, hypotonia, autistic features, and feeding difficulties, and same-domain missense evidence is stronger. The variant remains technically convincing, apparently de novo with good parental coverage, absent from population data, and a good phenotype fit. Candidate 5 is not a disease candidate but is the central reanalysis context because it explains why the interpretation has changed. Candidate 2 has weakened relative to the original review because updated population, mechanism, and gene validity evidence are less supportive. Candidate 4 is likely a real inherited duplication but remains weak due to uncertain dosage and phenotype support. Candidate 1 remains broad, inherited, relatively frequent, and poorly specific. The safest next step is to prioritise Candidate 3 for formal clinical laboratory reanalysis review, document exactly what evidence has changed, avoid implying the original interpretation was simply wrong, and preserve formal classification and sign-off boundaries.",
  };